Amylon Therapeutics, a spin-off of Leiden based and NASDAQ-listed ProQR Therapeutics, receives € 300.000 from investment fund UNIIQ to develop a therapy against Katwijkse Ziekte, a disease which is characterized by brain bleedings. The investment was announced by Robert Strijk, City Council Member of Leiden, at the Leidse Schouwburg preceding the startup event HEB LEF 2017 in Leiden.
Author Archive for: Hans Dreijklufft
About Hans Dreijklufft
This author has yet to write their bio.Meanwhile lets just say that we are proud Hans Dreijklufft contributed a whooping 12 entries.